Abstract
Fifteen patients, with a median age of 19 years having severe aplastic anaemia (SAA) underwent human leucocyte antigen (HLA) identical sibling donor hematopoietic stem cell transplantation (HSCT) using conditioning regimens containing cyclophosphamide with antithymocyte globulin (ATG) or a combination of fludarabine and cyclophosphamide with or without ATG during December 2007 to May 2013. Cyclosporine and mini methotrexate were used as graft versus host disease (GVHD) prophylaxis. Graft source included peripheral blood stem cells in 11, bone marrow in 3 and both in 1. One patient had primary graft failure while 14 patients were engrafted with a median neutrophil and platelet engraftment time of 13.5 days. One patient had secondary graft rejection. Acute GVHD occurred in 3 patients and chronic GVHD in 4. One year death rate in engrafted patients was 14.28 %. At a mean follow-up of 21.2 months, 12 (80 %) are alive and well. One of the donors was a patient of haemophilia but the disease did not occur in the recipient. The graft was successful and the recipient is alive till date.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Scheinberg P, Young NS (2012) How I treat acquired aplastic anemia. Blood 120:1185–1196
Pokorski RJ (1998) 5-Year survival after bone marrow transplantation for aplastic anemia. J Insur Med 30:237–239
Storb R, Longton G, Anasetti C, Appelbaum FR, Beatty P, Bensinger W, Crawford S, Deeq HJ, Doney K, Fefer A et al (1992) Changing trends in marrow transplantation for aplastic anemia. Bone Marrow Transpl 10(suppl 1):45–52
Schuening F, Bean MA, Deeg HJ, Storb R (1993) Prevention of graft failure in patients with aplastic anemia. Bone Marrow Transpl 3(12Suppl):S48–S49
Gluckman E, Socie G, Devergie A, Bourdeau-Esperou H, Traineau R, Cosset JM (1991) Bone marrow transplantation in 107 patients with severe aplastic anemia using cyclophosphamide and thoraco-abdominal irradiation for conditioning: long-term follow-up. Blood 78:2451–2455
Young NS, Calado RT, Scheinberg P (2006) Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 108(8):2509–2519
George B, Mathews V, Viswabandya A, Kavitha ML, Srivastava A, Chandy M (2007) Fludarabine and cyclophosphamide based reduced intensity conditioning (RIC) regimens reduce rejection and improve outcome in Indian patients undergoing allogeneic stem cell transplantation for severe aplastic anemia. Bone Marrow Transpl 40(1):13–18
Locatelli F, Bruno B, Zecca M, Van –Lint MT, McCann S, Arcese W, Dallorso S, Di Bartolomeo P, Fagioli F, Locasciulli A, Lawler M, Baciqalupo A (2000) Cyclosporin A and short term methotrexate versus cyclosporine A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogenic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial. Blood 96(5):1690–1697
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Raut, S.S., Shah, S.A., Patel, K.A. et al. Improving Outcome of Aplastic Anaemia with HLA-Matched Sibling Donor Hematopoietic Stem Cell Transplantation: An Experience of Gujarat Cancer and Research Institute (GCRI). Indian J Hematol Blood Transfus 31, 1–8 (2015). https://doi.org/10.1007/s12288-014-0397-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12288-014-0397-x